Physician

Vanessa N Ohnes-Verduguez, M.D.

According to 2025 Medicare claims, Vanessa Ohnes-Verduguez, M.D. (NPI: 1396988770) practices internal medicine in the Sherman-Denison, TX market, with the plurality of this provider's patient population coming from Grayson, TX. This provider's primary affiliated billing organization is TEXOMACARE (NPI: 1740233592; TIN: 752617462) and primary practice location at 75020-4587. Ohnes-Verduguez is affiliated with the Texoma Clinical Partners ACO, LLC (ACO ID: A4585), participating under the MSSP model.

Ohnes-Verduguez's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 444 traditional Medicare patients, billed 14,173 HCPCS/CPT codes, and received $345,508 in Medicare payments. The top billing code was 80061 (Blood test, lipids (cholesterol and triglycerides)). Part D data shows 9,896 prescription claims across 676 beneficiaries totaling $562,523 in drug costs, led by Ozempic (Semaglutide). DME data shows 100 claims. Open Payments data shows 12 records totaling $227. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Similarly, Part D prescription costs have changed little. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $25,507 and ending at $12,975.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	597	13,525	$349,392
2016	612	18,108	$385,591
2017	689	22,935	$419,412
2018	663	18,272	$418,687
2019	608	14,822	$386,861
2020	595	11,636	$307,036
2021	612	13,500	$343,699
2022	527	13,438	$310,628
2023	473	12,627	$304,929
2024	444	14,173	$345,508

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	511	10,809	$601,787
2016	557	11,107	$618,955
2017	761	11,693	$735,373
2018	709	11,438	$702,049
2019	657	10,326	$617,828
2020	681	9,693	$624,033
2021	715	10,509	$615,030
2022	696	10,031	$639,474
2023	681	10,168	$685,663
2024	676	9,896	$562,523

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	129	512	$19,733
2016	104	437	$9,355
2017	76	420	$7,209
2018	81	551	$9,864
2019	104	510	$10,617
2020	60	228	$4,409
2021	44	222	$8,636
2022	15	118	$5,472
2023	15	145	$7,606
2024	22	100	$7,991

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
80061	Blood test, lipids (cholesterol and triglycerides)	412	789	$13
80053	Blood test, comprehensive group of blood chemicals	424	910	$10
83036	Hemoglobin a1c level	405	673	$9
36415	Insertion of needle into vein for collection of blood sample	421	909	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	422	881	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Ozempic	Semaglutide	61	2,322	$68,456
Mounjaro	Tirzepatide	38	1,208	$45,126
Eliquis	Apixaban	49	1,993	$33,214
Trulicity	Dulaglutide	16	842	$28,875
Prolia	Denosumab	15	2,610	$26,315

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
A4239	Supply allowance for non-adjunctive, non-implanted continuous glucose monitor (cgm), includes all supplies and accessories, 1 month supply = 1 unit of service	N	N/R	11	$6,661
A4253	Blood glucose test or reagent strips for home blood glucose monitor, per 50 strips	N	11	27	$325
K0001	Standard wheelchair	Y	N/R	13	$307
Q0513	Pharmacy dispensing fee for inhalation drug(s); per 30 days	N	N/R	11	$260
A7038	Filter, disposable, used with positive airway pressure device	N	11	14	$212

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	12	$227	Phathom Pharmaceuticals, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Vanessa N. Ohnes-Verduguez, M.D.?

Tedicare shows public-source Medicare data for Vanessa N. Ohnes-Verduguez, M.D. (NPI 1396988770), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Vanessa N. Ohnes-Verduguez, M.D. have ACO affiliation data?

Vanessa N. Ohnes-Verduguez, M.D. is shown with ACO affiliation data for Texoma Clinical Partners ACO, LLC (MSSP, ACO ID A4585).

What billing organization is linked to Vanessa N. Ohnes-Verduguez, M.D.?

Vanessa N. Ohnes-Verduguez, M.D. is linked to TEXOMACARE (billing NPI 1740233592) in the available physician profile data.

Does Vanessa N. Ohnes-Verduguez, M.D. have Open Payments data?

Vanessa N. Ohnes-Verduguez, M.D. has 12 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.